Profile data is unavailable for this security.
About the company
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
- Revenue in USD (TTM)0.00
- Net income in USD-7.19m
- Incorporated2009
- Employees17.00
- LocationEdesa Biotech Inc100 Spy CrtMARKHAM L3R 5H6CanadaCAN
- Phone+1 (905) 475-1234
- Fax+1 (905) 475-1234
- Websitehttps://www.edesabiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Curative Biotechnology Inc | 0.00 | -6.02m | 7.75m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.29m | -10.87m | 8.05m | 16.00 | -- | 1.26 | -- | 2.45 | -17.27 | -17.27 | 5.09 | 3.98 | 0.3025 | 2.74 | 5.08 | 205,752.50 | -100.21 | -73.55 | -191.77 | -123.30 | 43.08 | -- | -331.26 | -476.22 | 0.7618 | -- | 0.0392 | -- | -1.90 | 74.49 | -4.06 | -- | -- | -- |
| StimCell Enegetics Inc | 0.00 | -935.22k | 8.09m | 0.00 | -- | -- | -- | -- | -0.0461 | -0.0461 | 0.00 | -0.0738 | 0.00 | -- | -- | -- | -2,062.23 | -844.03 | -- | -- | -- | -- | -- | -18,037.46 | -- | -17.22 | -- | -- | -- | -- | -297.42 | -- | -- | -- |
| Curanex Pharmaceuticals Inc | 0.00 | -1.30m | 8.12m | -- | -- | 0.5679 | -- | -- | -0.0497 | -0.0497 | 0.00 | 0.5043 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.76 | 0.00 | -- | -- | -- | -1,782.87 | -- | -- | -- |
| Hi-Great Group Holding Co | 48.03k | -64.27k | 8.21m | -- | -- | -- | -- | 170.94 | -0.0006 | -0.0006 | 0.0005 | -0.002 | 0.7229 | 0.5559 | -- | -- | -96.73 | -21.81 | -- | -256.35 | 38.77 | 45.63 | -133.81 | -21.02 | 0.0288 | -- | -- | -- | -36.79 | -- | 60.07 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -27.16m | 8.45m | 7.00 | -- | 5.38 | -- | -- | -354.09 | -354.09 | 0.00 | 1.71 | 0.00 | -- | -- | 0.00 | -592.26 | -153.21 | -1,387.56 | -219.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.49 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.19m | 8.52m | 17.00 | -- | 2.28 | -- | -- | -1.35 | -1.35 | 0.00 | 1.74 | 0.00 | -- | -- | 0.00 | -82.86 | -103.16 | -99.57 | -123.95 | -- | -- | -- | -- | -- | -138.68 | 0.00 | -- | -- | -- | -16.46 | -- | -- | -- |
| Bioatla Inc | 0.00 | -64.71m | 8.86m | 61.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.5313 | 0.00 | -- | -- | 0.00 | -165.61 | -49.22 | -317.99 | -57.35 | -- | -- | -- | -3,690.17 | -- | -- | -- | -- | -- | 16.17 | 43.48 | -- | -- | -- |
| Pulmatrix Inc | 3.00k | -6.22m | 8.89m | 2.00 | -- | 1.88 | -- | 2,964.44 | -1.70 | -1.70 | 0.0008 | 1.30 | 0.0004 | -- | -- | 1,500.00 | -75.43 | -42.08 | -79.47 | -49.93 | -- | -- | -207,333.30 | -210.36 | -- | -- | 0.00 | -- | 6.96 | -0.2644 | 32.31 | -- | 46.99 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -10.09m | 9.29m | 16.00 | -- | 0.8276 | -- | -- | -5.87 | -5.87 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -60.63 | -- | -72.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Ernexa Therapeutics Inc | 1.00k | -18.36m | 9.32m | 6.00 | -- | 0.7104 | -- | 9,319.69 | -5.32 | -5.32 | 0.0002 | 0.4548 | 0.0001 | -- | 0.0059 | 166.67 | -264.07 | -187.10 | -2,044.59 | -237.72 | 100.00 | -- | -1,834,000.00 | -3,375.91 | -- | -2.73 | 0.00 | -- | 755.88 | -50.61 | -105.47 | -- | -19.54 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 31 Dec 2025 | 687.50k | 8.25% |
| Velan Capital Investment Management LPas of 31 Dec 2025 | 687.50k | 8.25% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 687.50k | 8.25% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 625.00k | 7.50% |
| DRW Securities LLCas of 31 Dec 2025 | 134.22k | 1.61% |
| Geode Capital Management LLCas of 31 Dec 2025 | 46.54k | 0.56% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 37.14k | 0.45% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 18.68k | 0.22% |
| G1 Execution Services LLCas of 30 Sep 2025 | 14.61k | 0.18% |
| Citadel Securities LLCas of 30 Sep 2025 | 14.03k | 0.17% |
